Zoetis Inc. which can be found using ticker (ZTS) have now 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 260 and 180 with the average target price sitting at $214.92. Given that the stocks previous close was at $175.78 this would indicate that there is a potential upside of 22.3%. It’s also worth noting that there is a 50 day moving average of $168.86 and the 200 moving average now moves to $160.33. The company has a market cap of $83,057m. Find out more information at: https://www.zoetis.com
The potential market cap would be $101,551m based on the market consensus.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
The company has a dividend yield of 0.85% with the ex dividend date set at 20-4-2023 (DMY).
Other points of data to note are a P/E ratio of 40.08, revenue per share of 17.23 and a 12.73% return on assets.
